When you start taking a medication and notice something different in your body, a question may follow: Is the medication to blame?
Changes to your nails might also prompt this question.
In a new study, researchers studying GLP-1 drugs used to treat obesity and type 2 diabetes wanted to know if nail problems were more common in people who took them.
Turns out their study of 1,904 people across four countries found a difference.
Nail peeling was reported by 39 percent of GLP-1 users, compared to 9 percent of people with type 2 diabetes or obesity who had never taken the drug.
However, about half of addicts reported nail problems before treatment began.
The results were presented at the 2026 Congress of the European Academy of Dermatology and Venereology (EADV) in Vienna.
The researchers compared 575 GLP-1 users to 1,329 people with type 2 diabetes or obesity who had never used the drug, recruited in France, the United States, Brazil and Mexico.
According to an EADV press release, 66 percent of users reported at least one nail disorder, compared to 53 percent of controls. Nail discoloration was reported by 46 percent of GLP-1 users compared to 17 percent of controls.
“Our results show a clear association, but they also highlight an important point,” says study author Charles Taïeb, director general of the European Market Maintenance Assessment.
“Not everything that happens during GLP-1 treatment is necessarily due to the treatment itself.”
The study relied on participants describing their symptoms. This was a cross-sectional study, capturing their experiences at one point in time rather than following them throughout a course of treatment with standardized dermatological exams. This means it cannot establish that the medications caused the changes.
The extent of nail detachment described in the study is also unclear. Researchers have not clarified whether this covers partial separation of the nail bed, complete loss of the nail, or both, and currently available information does not distinguish between fingernails and toenails.
In general, the separation of the nail plate from its bed is called onycholysis. DermNet explains that this can affect the fingers or toes and can have several causes, including injuries, skin diseases and infections. This context does not establish the conditions experienced by the participants in this study.
The figure of 39 percent should therefore not be interpreted as evidence that almost four out of ten users have completely lost their nails. It also does not estimate the risk of a new patient developing the problem after treatment begins.
The researchers took dermatological problems and nutritional deficiencies into account when analyzing the results. Some associations weakened, but nail peeling and discoloration remained about two to three times more common among users, according to the release.
Exact adjusted estimates and confidence intervals are not provided. Without them, the accuracy of these comparisons cannot be assessed from the ad alone.
The team also looked at weight loss. The differences remained statistically significant when the analysis focused on participants who lost weight, suggesting that weight loss alone may not explain the results. This still does not demonstrate a direct effect on the nails.
A follow-up study involving the same participants examined hair and scalp symptoms, further increasing interest in possible links between GLP-1 pathways and hair loss.
Unusual hair loss was reported by 50 percent of users compared to 34 percent of controls. Reducing hair volume or density affected 42 percent versus 19 percent.
In users, hair loss was usually accompanied by scalp symptoms such as itching, redness, or flaking.
Study author and dermatologist Bruno Halioua of the Société Française des Sciences Humaines sur la Peau (SFSHP) suggests that this pattern could go beyond the shedding typically seen after rapid weight loss and involve inflammation.
The hair results come from the same group of people, so they do not independently replicate the nail results. Instead, they offer another view of the symptoms reported in this sample.
Whether similar trends appear in other populations and how often problems arise after treatment begins remains a question to be answered by research.
The release does not identify which GLP-1 medications participants took or provide results for any specific medication. The results cannot therefore establish an effect on the nails linked to a particular drug.
The release cites conference presentations as sources for both studies; it does not refer to a published article reporting them.
The study on nails was carried out with the institutional support of Laboratoires DUCRAY, Pierre Fabre group, which develops dermatological and hair products.
The researchers now plan to follow patients from the start of treatment. Standardized dermatologic exams and laboratory monitoring could help determine when changes occur, what contributes to them, and whether they are reversible.
Halioua describes the changes as frequent and generally mild. For people who notice changes in their nails, hair loss, or itching or redness on the scalp, her advice is to discuss these symptoms with their doctor rather than stopping treatment themselves.
This article was fact-checked by Rachel Garner and edited by Peter Dockrill. Although we are proud of our process, we are only human. If you spot an error, please let us know.
Gn Health
